Animal Dermatology Group

ADG operates a network of veterinary dermatology specialty practices staffed by board-certified veterinarians. The group treats chronic skin, ear, and allergic conditions in dogs and cats — conditions that general-practice vets frequently refer to specialists. ADG also runs a central laboratory that manufactures custom allergy immunotherapy serums, creating a pharmaceutical revenue line alongside clinical services.

ADG places clinical leadership in the hands of board-certified veterinary dermatologists rather than lay administrators. This specialist-led governance structure is intended to preserve treatment quality as the group scales, and it distinguishes ADG from private-equity-backed consolidators where clinician autonomy often erodes post-acquisition.

Patients are overwhelmingly referrals from general-practice veterinarians who recognize that a chronic dermatological condition exceeds their diagnostic or therapeutic capabilities. These referral relationships are sticky because dermatology cases require ongoing management, creating repeat visits and long-term serum prescriptions that sustain clinic volume and lab revenue.

ADG has not publicly named a private equity sponsor or disclosed its capitalization structure. Its multi-site partnership model and geographic expansion pattern are consistent with institutional backing, but no specific fund or sponsor is confirmed in public filings or the firm's own communications.

Board-certified veterinary dermatologists are an extremely scarce resource — fewer than 400 diplomates of the American College of Veterinary Dermatology practice in the United States. The chronic and recurrent nature of allergic skin disease generates a recurring-revenue profile from both clinical visits and immunotherapy serum refills, and the referral-based patient acquisition model reduces marketing spend relative to general practice.